Roche: collaboration agreement with Semathera
(CercleFinance.com) - SemaThera announced on Monday that it has signed a multi-year research and licensing agreement with Swiss biopharmaceutical giant Roche.
The partnership between the Montreal-based biotech group and the Basel-based pharmaceutical giant will focus on the use of tissue markers in the treatment of diabetic retinopathy and other retinal diseases.
In a statement, Roche explains that this is one of its priority areas of interest in ophthalmology.
SemaThera's activities focus on the development of new therapies for diseases such as diabetic macular edema and age-related macular degeneration.
SemaThera was launched in 2016 by the venture capital fund AmorChem following an investment in the laboratory of Mike Sapieha, a professor at Maisonneuve Rosemont Hospital.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The partnership between the Montreal-based biotech group and the Basel-based pharmaceutical giant will focus on the use of tissue markers in the treatment of diabetic retinopathy and other retinal diseases.
In a statement, Roche explains that this is one of its priority areas of interest in ophthalmology.
SemaThera's activities focus on the development of new therapies for diseases such as diabetic macular edema and age-related macular degeneration.
SemaThera was launched in 2016 by the venture capital fund AmorChem following an investment in the laboratory of Mike Sapieha, a professor at Maisonneuve Rosemont Hospital.
Copyright (c) 2021 CercleFinance.com. All rights reserved.